急性髓性白血病(AML)是一成年人的疾病,其发病率随年龄的增加而增加,其中数年龄为65～70岁。由于患者的治疗禁忌证以及医生和患者对化疗及其毒性所持保守态度,临床报道的中数发病年龄比上述要低15～20岁。绝大多数的临床观察显示老年AML的治疗效果差,生存期较年轻组为短,因此有必要探讨其原因并制定适合于老年AML的治疗方针。 Acute myeloid leukemia (AML) is an adult disease whose incidence increases with age, with ages ranging from 65 to 70 years. Because of the patient’s treatment contraindications and the conservative attitude of doctors and patients to chemotherapy and its toxicity, the clinically reported median age of onset is 15 to 20 years less than the above. The vast majority of clinical observations show that the efficacy of treatment of elderly AML is poor, and the survival period is shorter than that of the younger group. Therefore, it is necessary to explore the causes and formulate treatment guidelines suitable for elderly AML.